Kinnate Biopharma (KNTE) Social Stream
KINNATE BIOPHARMA INC (KNTE) Price Targets From Analysts
Use the tables below to see what analysts covering KINNATE BIOPHARMA INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-28 | 6 | $52 | $32 | $46.4 | $5.51 | 742.11% |
| 2021-11-11 | 6 | $53 | $32 | $47 | $5.51 | 752.99% |
| 2022-02-02 | 6 | $52 | $35 | $45.8 | $5.51 | 731.22% |
| 2022-03-29 | 6 | $52 | $33 | $42 | $5.51 | 662.25% |
| 2022-05-12 | 6 | $52 | $33 | $41 | $5.51 | 644.1% |
| 2022-05-13 | 6 | $52 | $33 | $39.8 | $5.51 | 622.32% |
| 2022-05-18 | 7 | $46 | $30 | $35.4 | $5.51 | 542.47% |
| 2022-07-27 | 7 | $46 | $29 | $34.333 | $5.51 | 523.1% |
| 2022-10-26 | 8 | $46 | $29 | $34.142 | $5.51 | 519.64% |
| 2022-11-11 | 8 | $46 | $29 | $33.571 | $5.51 | 509.27% |
| 2023-02-07 | 8 | $46 | $11 | $30.142 | $5.51 | 447.04% |
| 2023-02-26 | 8 | $36 | $11 | $28.714 | $5.51 | 421.13% |
| 2023-03-16 | 8 | $36 | $8 | $27.714 | $5.51 | 402.98% |
The Trend in the Analyst Price Target
KNTE's average price target has moved down $24.29 over the prior 26 months.
Over the past 50 weeks, KNTE's average upside potential has been 257.9%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-05-18 | 6 | 46 | 30 | 35.400 | 9.96 | 255.42% |
| 2022-05-24 | 7 | 46 | 29 | 34.333 | 9.93 | 245.75% |
| 2022-07-28 | 8 | 46 | 29 | 34.142 | 11.67 | 192.56% |
| 2022-09-12 | 8 | 46 | 29 | 34.142 | 14.46 | 136.11% |
| 2022-10-26 | 8 | 46 | 29 | 34.142 | 8.51 | 301.2% |
KNTE Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.25 | 7 | 0 | 1 | 0 | 0 | 8 |
The Trend in the Broker Recommendations
Over the past 16 months, KNTE's average broker recommendation rating worsened by 0.25.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how KINNATE BIOPHARMA INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 1301.75% of that group.
- In the context of stocks in the small market cap category, KINNATE BIOPHARMA INC's number of analysts covering the stock is higher than 1151.96% of them.
- In the context of stocks in the small market cap category, KINNATE BIOPHARMA INC's average analyst price target is greater than 1123.31% of them.
- In the context of Pharmaceutical Products stocks, KINNATE BIOPHARMA INC's variance in analysts' estimates is lower than -454.31% of them.
Stocks similar to KINNATE BIOPHARMA INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are SGTX, NBTX, and PHAR.
View All Top Stocks by Price Target
Make investment decisions regarding KNTE using the data that counts. Try POWR Ratings for free.